Thus, IBCs with PIWIL2–PIWIL4 downregulation could benefit from immunotherapy by using checkpoints inhibitors because of an important cytotoxic immune reaction and reexpression of many neoantigens and TEs by cancer cells. This evidence concerns the gene PIWIL4 and cancer.